Daclizumab Side Effects
Medically reviewed by Drugs.com. Last updated on Feb 14, 2024.
Applies to daclizumab: intravenous solution.
Warning
Intravenous route (Solution)
Only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe daclizumab, and they should have complete information requisite for the follow-up of the patient. Daclizumab should only be administered by healthcare personnel trained in the administration of the drug who have available adequate laboratory and supportive medical resources.
Serious side effects of Daclizumab
Along with its needed effects, daclizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking daclizumab:
Less common
- Chest pain
- coughing
- dizziness
- fever
- nausea
- rapid heart rate
- red, tender, and oozing skin at incision
- shortness of breath
- swelling of the feet or lower legs
- trembling or shaking of the hands or feet
- vomiting
- weakness
Rare
- Frequent urination
Other side effects of Daclizumab
Some side effects of daclizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
- Constipation
- diarrhea
- headache
- heartburn
- itching, pain, redness, swelling, tenderness, or warmth on skin
- joint pain
- muscle pain
- slow wound healing
- trouble with sleeping
For Healthcare Professionals
Applies to daclizumab: intravenous solution, subcutaneous solution.
Cardiovascular
Common (1% to 10%): Lymphadenopathy, lymphadenitis[Ref]
Dermatologic
Very common (10% or more): Rash (i.e., erythematous rash, exfoliative rash, macular rash, maculopapular rash, papular rash, pruritic rash, rash, vesicular rash) (11%)
Common (1% to 10%): Dermatitis (i.e., allergic dermatitis, atopic dermatitis, bullous dermatitis, dermatitis, exfoliative dermatitis, seborrheic dermatitis, eczema, allergic dermatitis), folliculitis, acne, psoriasis, erythema, pruritus, dry skin
Uncommon (0.1% to 1%): Toxic skin eruption, eczema nummular[Ref]
Gastrointestinal
Common (1% to 10%): Tonsillitis, diarrhea
Frequency not reported: Colitis[Ref]
Hematologic
Common (1% to 10%): Anemia, lymphocyte count decreased[Ref]
Hypersensitivity
Frequency not reported: Anaphylaxis[Ref]
Respiratory
Very common (10% or more): Nasopharyngitis (25%), upper respiratory tract infection (17%)
Common (1% to 10%): Bronchitis, pneumonia, laryngitis, rhinitis[Ref]
Psychiatric
Common (1% to 10%): Depression[Ref]
Other
Common (1% to 10%): Oropharyngeal pain, pyrexia[Ref]
Hepatic
Common (1% to 10%): ALT increased, AST increased, liver function test abnormal, hepatic enzymes increased[Ref]
Immunologic
Common (1% to 10%): Influenza, viral infection[Ref]
Frequently asked questions
More about daclizumab
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: interleukin inhibitors
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. Cerner Multum, Inc. UK Summary of Product Characteristics.
2. Cerner Multum, Inc. Australian Product Information.
3. Product Information. Zinbryta (daclizumab). AbbVie US LLC. 2016.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
